Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

BACKGROUND: Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechalle...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, Bilal A, Gheeya, Jinesh S, Goswamy, Rohit, Bathala, Tharakeswara K, Surasi, Devaki Shilpa, Gao, Jianjun, Shah, Amishi, Campbell, Matthew T, Msaouel, Pavlos, Goswami, Sangeeta, Wang, Jennifer, Zurita, Amado J, Jonasch, Eric, Corn, Paul G, Aparicio, Ana M, Siefker-Radtke, Arlene O, Sharma, Padmanee, Subudhi, Sumit K, Tannir, Nizar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323401/
https://www.ncbi.nlm.nih.gov/pubmed/34326169
http://dx.doi.org/10.1136/jitc-2021-002850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323401/
https://www.ncbi.nlm.nih.gov/pubmed/34326169
http://dx.doi.org/10.1136/jitc-2021-002850

Ejemplares similares